Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells

[Image: see text] Acquired resistance to MAPK inhibitors limits the clinical efficacy in melanoma treatment. We and others have recently shown that BRAF inhibitor (BRAFi)-resistant melanoma cells can develop a dependency on the therapeutic drugs to which they have acquired resistance, creating a vul...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bohui, Kong, Xiangjun, Post, Harm, Raaijmakers, Linsey, Peeper, Daniel S., Altelaar, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419860/
https://www.ncbi.nlm.nih.gov/pubmed/34343000
http://dx.doi.org/10.1021/acs.jproteome.1c00331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419860/
https://www.ncbi.nlm.nih.gov/pubmed/34343000
http://dx.doi.org/10.1021/acs.jproteome.1c00331

Ejemplares similares